Clinical outcome and gut development after insulin-like growth factor-1 supplementation to preterm pigs.

ABSTRACT:

Background

Elevation of circulating insulin-like growth factor-1 (IGF-1) within normal physiological levels may alleviate several morbidities in preterm infants but safety and efficacy remain unclear. We hypothesized that IGF-1 supplementation during the first 1-2 weeks after preterm birth improves clinical outcomes and gut development, using preterm pigs as a model for infants.

Methods

Preterm pigs were given vehicle or recombinant human IGF-1/binding protein-3 (rhIGF-1, 2.25 mg/kg/d) by subcutaneous injections for 8 days (Experiment 1, n = 34), or by systemic infusion for 4 days (Experiment 2, n = 19), before collection of blood and organs for analyses.

Results

In both experiments, rhIGF-1 treatment increased plasma IGF-1 levels 3-4 fold, reaching the

SUBMITTER: Holgersen K 

PROVIDER: S-EPMC9389362 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature